Pragmatic concerns could temper anti-China biotech policies

Legislation seeking to prevent some Chinese biotech companies from operating in the U.S. is being buffeted by crosswinds. Intensifying geopolitical tensions and bipartisan animosity toward China are pushing the legislation forward, while congressional dysfunction and gale-force election-year partisanship are pushing back. Deadlock could create space for compromise.

As BioCentury editors discussed Thursday on a special edition of the BioCentury This Week podcast, even if the pending legislation is not enacted, sooner or later Congress and the White House will act on the alarms the U.S. national security community is raising about China’s genomics companies and contract manufacturing and development organizations (CDMOs). ...